In2cure, a biotech company, develops new peptide-based therapeutics to prevent infections and control inflammation. As the problem of multidrug resistance (MDR) is growing rapidly, the possibility to prevent and treat bacterial infections with antibiotics is becoming more and more limited. It is therefore critical to find alternative ways to prevent infections, also effective on MDR, and to treat the uncontrolled hazardous inflammation, which often is what hinders the wounds from healing and causes death in the case of sepsis.
In2cure’s BioC platform is an antibiotic-free treatment utilizing the body’s natural defense system. It is unique in the way that it has both anti-bacterial and anti-inflammatory properties. It kills bacteria by binding to the bacteria cell wall inducing lysis and it reduces the hazardous inflammation by both neutralizing endotoxins and preventing the inflammatory signaling on CD14 level.
In2cure’s technology has the potential to be effective for several indications, both topical and systemic. The company’s first product will be used for advanced wound care, initially targeting burn wounds. The BioC wound gel is currently in preclinical phase and has been shown to be very effective in animal models (rodent and pigs).
“We are looking forward to the input and discussions with our mentor team on topics like commercial and regulatory strategy. With their experience and networks, we also hope to identify and engage potential partners within wound care and make in2cure a strong business case.”
In2cure stands on a solid scientific foundation from Lund University. Helene Hartman took over as CEO in 2018 after first being a member of the board of directors. She is supported by a strong team with backgrounds in research and business development. In2cure is located in Lund, Sweden, and joined NOME in 2019.